Investment Analysts’ Weekly Ratings Changes for Vigil Neuroscience (VIGL)

Vigil Neuroscience (NASDAQ: VIGL) recently received a number of ratings updates from brokerages and research firms:

• 5/28/2025 – Vigil Neuroscience was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $8.00 price target on the stock, down previously from $11.00.
• 5/27/2025 – Vigil Neuroscience was downgraded by analysts at HC Wainwright from a “strong-buy” rating to a “hold” rating. They now have a $8.00 price target on the stock, down previously from $14.00.
• 5/23/2025 – Vigil Neuroscience was downgraded by analysts at Mizuho from a “strong-buy” rating to a “hold” rating.
• 5/22/2025 – Vigil Neuroscience was downgraded by analysts at Jefferies Financial Group Inc. to a “hold” rating.
• 5/22/2025 – Vigil Neuroscience was given a new $8.00 price target on by analysts at Guggenheim. They now have a “neutral” rating on the stock.
• 5/22/2025 – Vigil Neuroscience was downgraded by analysts at Citigroup Inc. to a “market perform” rating.
• 5/22/2025 – Vigil Neuroscience had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 5/22/2025 – Vigil Neuroscience was downgraded by analysts at Guggenheim from a “strong-buy” rating to a “hold” rating.
• 5/22/2025 – Vigil Neuroscience was downgraded by analysts at Citizens Jmp from a “strong-buy” rating to a “hold” rating.
• 5/22/2025 – Vigil Neuroscience was downgraded by analysts at Wedbush from a “strong-buy” rating to a “hold” rating. They now have a $8.00 price target on the stock, down previously from $13.00.
• 5/22/2025 – Vigil Neuroscience was downgraded by analysts at William Blair from a “strong-buy” rating to a “hold” rating.
• 5/5/2025 – Vigil Neuroscience had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $13.00 price target on the stock.
• 4/24/2025 – Vigil Neuroscience was upgraded by analysts at William Blair to a “strong-buy” rating.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL traded up $0.01 during trading on Wednesday, hitting $7.89. 1,950,932 shares of the stock were exchanged, compared to its average volume of 647,938. Vigil Neuroscience, Inc. has a 1-year low of $1.31 and a 1-year high of $7.95. The company has a market capitalization of $368.24 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. The company’s fifty day simple moving average is $2.43 and its 200-day simple moving average is $2.35.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. On average, research analysts forecast that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of Vigil Neuroscience

A number of hedge funds have recently made changes to their positions in VIGL. Cubist Systematic Strategies LLC increased its stake in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after purchasing an additional 8,358 shares during the period. Jane Street Group LLC bought a new position in Vigil Neuroscience during the 4th quarter worth $83,000. Barclays PLC increased its stake in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after purchasing an additional 19,436 shares during the last quarter. Northern Trust Corp increased its stake in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after purchasing an additional 14,572 shares during the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after purchasing an additional 49,000 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.